Purchase Order 75D30124P19870
Award Date
9/26/24
Potential Completion Date
9/24/26
Potential Value
$249K
Federal Agency
CDC Pittsburgh
Awardee
Bioreliance Corporation
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lakewood, CO 80225, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Bioreliance Corporation, a foreign-owned, for-profit organization, for the storage of Vero and MDCK cells in liquid nitrogen under compliant Good Manufacturing Practice (cGMP) and compliant Good Laboratory Practice (cGLP) conditions. The contract has a ceiling value of $131,226.00 and a period of performance ending on May 31, 2026. The contract was awarded on a sole-source basis, as the...
Bioreliance Corporation was awarded a firm fixed price purchase order totaling one hundred thirteen thousand one hundred ninety-six dollars and ten cents ($113,196.10) by the Centers for Disease Control and Prevention (CDC) for storage renewal of Vero and MDCK cell banks. To be performed in Atlanta, Georgia, the contract has a period of performance through May 31, 2020 but does not include any set aside designations. As the prime contractor, Bioreliance will provide continued storage of cell...
This is a definitive contract award to Bioreliance Corporation, a foreign-owned, for-profit organization, by the Centers for Disease Control and Prevention (CDC) Pittsburgh office. The $672,262.42 firm-fixed-price contract is for BIORELIANCE EXPI293F services, which likely includes specialized microbiological and scientific testing capabilities to support pharmaceutical and biotechnology research, such as endotoxin testing, sterility testing, and Limulus Amebocyte Lysate (LAL) testing. The...
This is a firm fixed-price delivery order awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Bioreliance Corporation for $127,772.70. The contract is for biosafety testing of GMP (Good Manufacturing Practice) master cell banks, a critical step in the development of new pharmaceutical products. Bioreliance, a foreign-owned, for-profit company, has extensive experience providing microbiological testing services to federal health...
This federal contract award is for an order to fund the minimum for Option Period 1 for master cell bank testing, awarded to Bioreliance Corporation, a foreign-owned, for-profit organization that provides specialized testing services to the U.S. government. The contract, issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), has a firm fixed price of $94,587.25 and a completion date of July 24, 2015. Bioreliance...
This is a delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Bioreliance Corporation, a foreign-owned for-profit organization. The $83,273.28 firm fixed-price contract is for Option Year 1 of Contract HHSN261200900022I, which covers master cell bank testing, specifically sterility testing under Package 1, Line Item 32. Bioreliance Corporation, through its Life Sciences Services division, provides endotoxin,...
This federal contract award, valued at $32,797.00, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Bioreliance Corporation, a foreign-owned, for-profit organization that provides specialized testing services. The contract is for vector biosafety testing, including sterility testing of vector supernatant samples. Bioreliance has a history of supporting various government health initiatives, including providing services to...
The Centers for Disease Control and Prevention (CDC) awarded a $249,662 purchase order to Cell Microsystems Inc. to procure cell lines in support of the agency's biomedical research and public health initiatives. The firm fixed price contract has a period of performance from September 11, 2023 through October 30, 2023 for delivery of the requested cell lines to CDC facilities in Durham, North Carolina. No subcontractors or set aside designations were identified. This award advances the CDC's...
This federal contract award is for a Definitive Contract with a Ceiling Value of $410,000.00. The contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization that provides specialized testing services to the U.S. government, particularly the Department of Health and Human Services. The contract is for "BIOMEDICAL (BASIC)" services, which primarily include endotoxin, sterility, and general safety testing in support of investigational new drug...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned, for-profit organization. The contract, valued at $127,772.70, is for biosafety testing of a 293T master cell bank used for production of patient-specific lentiviral vectors encoding. This contract does not have a set-aside designation, indicating Bioreliance's competitive standing in the...